Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa

Table 3 QALYs, Costs and ICERs per treatment arm

Treatment arm	Cost (USD)	QALY	ICER
1-week AmBd/Flu	1873	8.15	–
2-week AmBd/Flu (SC)	2208	10.44	Weakly dominated^a
Oral 5FC/Flu	2472	11.69	Weakly dominated^a
1-week AmBd/5FC	2698	15.08	119
2-week AmBd/5FC	2731	11.28	Dominated^b

^a Weakly dominated; where mutually exclusive programmes are compared, and one option has a lower ICER than the next less costly option
^b Dominated; where at least one other treatment option has lower costs and higher benefits

ISSN: 1472-6963